Business Context and Reporting Period
Company: Silo Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 9, 2021
Event: Entry into a Material Definitive Agreement for a Series C Convertible Preferred Stock Financing.
Key Financial Metrics and Transaction Details
This filing details a private placement rather than standard operating financial results. Key transaction metrics include:
- Gross Proceeds: $4,276,000.
- Securities Issued: 4,276 shares of Series C Convertible Preferred Stock and warrants to purchase 14,253,333 shares of Common Stock.
- Warrant Exercise Price: $0.30 per share (5-year term).
- Preferred Stock Conversion Price: $0.30 per share (subject to anti-dilution adjustments).
- Placement Agent Warrants: Issued to purchase 2,850,667 shares (10% of securities sold) at an exercise price of $0.35 per share.
- Use of Proceeds: Working capital and execution of existing business.
Note: The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Terms
The primary material change is the capital raise and the associated terms of the new equity instruments:
- Anti-Dilution Protection: Conversion and exercise prices are subject to adjustment for subsequent lower price issuances.
- Beneficial Ownership Limitations: Investors are restricted from converting or exercising warrants if it results in ownership exceeding 4.99% or 9.99% (at investor election) of outstanding common stock.
- Participation Rights: Investors have the right to participate in subsequent financings for 18 months up to 50% of the new financing amount.
- Registration Rights: The Company must file a registration statement within 10 days and have it declared effective within 60 days (or 90 days if under full SEC review). Failure to do so triggers liquidated damages of 1% of the subscription amount per month.
- Lock-Up Agreements: All officers and directors are locked up for 90 days following the effective date of the registration statement.
Outlook, Risks, and Contingencies
- Liquidity Risk: The Company relies on the successful registration of the underlying securities to provide liquidity to investors; failure to register triggers financial penalties.
- Dilution Risk: The issuance of warrants and convertible preferred stock, combined with anti-dilution provisions, creates potential for significant future dilution to common shareholders.
- Management Commentary: The Company intends to use proceeds for working capital and business execution. No specific operational guidance or revenue forecasts were provided in this filing.
Investor Verification Checklist
- Verify the effective date of the registration statement for the resale of the underlying common stock to assess potential liquidated damages.
- Review the full Certificate of Designations (Exhibit 3.1) for specific details on dividend rights and liquidation preferences.
- Monitor the Company's capital structure for any subsequent lower-priced issuances that would trigger anti-dilution adjustments.
- Confirm the status of the 90-day lock-up agreement for officers and directors.
- Check for any press releases or subsequent filings regarding the actual net proceeds after deducting placement agent fees and offering expenses.